SummerHaven Investment Management LLC Purchases 1,367 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)

SummerHaven Investment Management LLC boosted its position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 1.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 74,146 shares of the company’s stock after buying an additional 1,367 shares during the quarter. SummerHaven Investment Management LLC’s holdings in Voyager Therapeutics were worth $626,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Kestra Advisory Services LLC acquired a new stake in shares of Voyager Therapeutics in the third quarter valued at about $980,000. Ritholtz Wealth Management grew its holdings in Voyager Therapeutics by 11.8% in the 4th quarter. Ritholtz Wealth Management now owns 19,759 shares of the company’s stock valued at $167,000 after buying an additional 2,089 shares during the last quarter. Alps Advisors Inc. bought a new position in Voyager Therapeutics in the 3rd quarter worth approximately $294,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Voyager Therapeutics during the fourth quarter worth approximately $43,000. Finally, Aigen Investment Management LP bought a new stake in shares of Voyager Therapeutics in the third quarter valued at approximately $109,000. Institutional investors own 48.03% of the company’s stock.

Wall Street Analyst Weigh In

VYGR has been the topic of a number of research reports. Wells Fargo & Company raised shares of Voyager Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $9.00 to $14.00 in a research report on Tuesday, January 2nd. Guggenheim initiated coverage on shares of Voyager Therapeutics in a report on Tuesday, March 26th. They set a “buy” rating and a $22.00 price objective on the stock. Citigroup began coverage on shares of Voyager Therapeutics in a research note on Thursday, March 7th. They issued a “buy” rating and a $16.00 target price for the company. StockNews.com raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, March 9th. Finally, HC Wainwright began coverage on Voyager Therapeutics in a report on Tuesday, March 19th. They issued a “buy” rating and a $30.00 price target for the company. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.33.

Voyager Therapeutics Stock Up 2.0 %

NASDAQ VYGR opened at $7.77 on Tuesday. Voyager Therapeutics, Inc. has a twelve month low of $6.06 and a twelve month high of $14.34. The stock has a market cap of $422.61 million, a P/E ratio of 2.51 and a beta of 0.96. The company’s 50-day simple moving average is $8.81 and its 200 day simple moving average is $7.97.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Wednesday, February 28th. The company reported $1.25 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $1.84. Voyager Therapeutics had a return on equity of 63.89% and a net margin of 52.93%. The company had revenue of $90.06 million for the quarter, compared to the consensus estimate of $4.95 million. Research analysts anticipate that Voyager Therapeutics, Inc. will post -1.64 earnings per share for the current year.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.